AMYL THERAPEUTICS
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
AMYL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2020-11-01
Address:
Liège, Liege, Belgium
Country:
Belgium
Website Url:
http://www.amyltx.com
Total Employee:
1+
Status:
Active
Total Funding:
29.7 M EUR
Technology used in webpage:
Euro CrUX Top 50m CrUX Dataset MediaElement.js
Similar Organizations
Cloudbreak Therapeutics
Cloudbreak Therapeutics is a clinical stage biotechnology company
Complement Therapeutics
Complement Therapeutics operates as a preclinical stage company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Freeline
Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
ExCellThera
ExCellThera is an advanced clinical stage biotechnology company.
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Relief Therapeutics
Relief Therapeutics is a clinical stage biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series A - Amyl Therapeutics
Evren Ucok
Evren Ucok investment in Series A - Amyl Therapeutics
Mérieux Equity Partners
Mérieux Equity Partners investment in Series A - Amyl Therapeutics
Kenneth Buckfire
Kenneth Buckfire investment in Series A - Amyl Therapeutics
6K Venture Capital
6K Venture Capital investment in Series A - Amyl Therapeutics
Ifoghas Investments
Ifoghas Investments investment in Series A - Amyl Therapeutics
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series A - Amyl Therapeutics
Smedvig
Smedvig investment in Series A - Amyl Therapeutics
Mérieux Equity Partners
Mérieux Equity Partners investment in Series A - Amyl Therapeutics
Sambrinvest
Sambrinvest investment in Series A - Amyl Therapeutics
Official Site Inspections
http://www.amyltx.com
- Host name: 51.83.12.214
- IP address: 51.83.12.214
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Amyl Therapeutics"
About – Amyl Tx
Since its creation, Amyl has prioritized fostering a supportive and dynamic workplace for all members of the organization. It provides an environment of exceptional scientific standards. Both scientists and support staff benefit from …See details»
Amyl Tx – Pan Amyloid Immunotherapy
Mar 26, 2025 Amyl Therapeutics is a preclinical-stage biotechnology company developing Pan-Amyloid Immunotherapy, a groundbreaking approach designed to become a universal …See details»
Home | Amylyx
Our mission would not be possible without each individual perspective within our talented organization. Amylyx has created a culture of caring and assembled an experienced team …See details»
Team Building Event & Leadership Transition Announcement
Sep 24, 2024 This occasion also marks an important leadership transition within our organization. We are delighted to introduce Damien Toulorge, our new Chief Scientific …See details»
Amyl Therapeutics - LinkedIn
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating severe peripheral amyloid protein misfolding diseases. By developing …See details»
Amyl Therapeutics - Crunchbase Company Profile & Funding
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including …See details»
Amyl Therapeutics - Merieux Partners
Amyl Therapeutics is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, they aim to …See details»
Amyl Therapeutics - EU-Startups
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases.See details»
Amyl Therapeutics - edgein.io
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing …See details»
Amyl Therapeutics - VentureRadar
"Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated diseases. Our scientists work on a proprietary technology, that is able to bind to various types …See details»
Amyl Therapeutics - BIO CEO & Investor Conference | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. Amyl Therapeutics - BIO CEO & …See details»
Amyl Therapeutics - Craft
Amyl Therapeutics $22.34 m in total funding,. See insights on Amyl Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Amyl Therapeutics (Belgium) Funding: €29.7M - Medical Startups
Apr 2, 2025 Amyl Therapeutics unique technology offers a curative solution for all forms of amyloid mediated...See details»
News - amyltx.com
This occasion also marks an important leadership transition within our organization. We are delighted to introduce Damien Toulorge, our new Chief Scientific Officer(CSO). Damien brings …See details»
Vision - amyltx.com
Progress and limitations of new treatments. We are entering an exciting era for treating neurodegenerative diseases, with a new wave of promising antibody-based products targeting …See details»
Amyl Therapeutics | BIO-Europe - Informa Connect
Amyl Therapeutics develops a novel therapeutic platform of therapeutics aiming at treating and curing diseases caused by amyloid fibrils. Our initial indications are the various forms of …See details»
Amyl Therapeutics obtient un financement additionnel de 5 …
Nov 7, 2023 www.amyltx.com. A propos de Mérieux Equity Partners Mérieux Equity Partners (MxEP) est une société de gestion agréée par l’AMF dédiée aux prises de participation dans le …See details»
Upcoming conferences – Amyl Tx
Mar 28, 2025 Our CEO, Pierre Vandepapelière, and our CSO, Damien Toulorge, will be attending Bio€quity on May 12-14 in Bruges. Presentation Tuesday 13th May 11:30 AM – …See details»
Amyloidosis: untangling the hardest knots ... - Nature
Www.amyltx.com Amyloidosis: untangling the hardest knots toclearorgansoftoxicplaques Amyl Therapeutics is developing a novel treatment for clearing misfolded proteins that aggregate …See details»
Amyl Therapeutics closes €18.3 million Series A financing to …
LIEGE, Belgium, June 3, 2021 /PRNewswire/ -- Amyl Therapeutics ('Amyl'), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named …See details»